TY - JOUR
T1 - American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy
AU - American Society for Transplantation and Cellular Therapy Committee on Education
AU - Jain, Tania
AU - Knight, Tristan
AU - Alencar, Maritza C.
AU - Davis, Laurie
AU - Rao, Kamakshi
AU - Im, Annie
AU - Malone, Adriana K.
N1 - Funding Information:
Financial disclosure and Conflict of interest statement: T.J. has received institutional research support from CTI Biopharma and Syneos Health, served as a consultant for Targeted Healthcare Communications, and served on advisory boards for Care Dx, Bristol Myers Squibb, and CTI. A.I. has served as a consultant for AbbVie. M.C.A. has served on the speaker's bureau for Kite Pharma. The other authors have no conflicts of interest to report. Authorship statement: All authors have made substantial contributions and agree to the following:, All authors have made substantial contributions to the conception or design of the work, including the acquisition, analysis, or interpretation of data for the work. All authors contributed to drafting or revising the work critically for important intellectual content. All authors have given final approval of the version to be published. All authors agree to be accountable for all aspects of the work, by ensuring that questions related to the accuracy or integrity of any part of the work are adequately addressed. Financial disclosure: See Acknowledgments on page 132.
Publisher Copyright:
© 2021 The American Society for Transplantation and Cellular Therapy
PY - 2022/3
Y1 - 2022/3
N2 - Rapid advances in the field of hematopoietic cell transplantation (HCT), as well as the advent of immune effector cell therapy (IEC), have resulted in an increasing number of patients undergoing these therapies and an increasing level of expertise required to manage them. Previous guidelines for the training of HCT physicians were last published in 2012. In recognition of the expanding knowledge base and increasing skill set essential to the delivery of these treatment modalities, the American Society for Transplantation and Cellular Therapy Committee on Education has updated these guidelines to reflect nearly a decade of new knowledge in the field of HCT, as well as the evolution of IEC from an experimental modality to a widely used and mainstream therapy. The resulting document reflects the Committee on Education's recommended educational structure for programs engaged in the training, evaluation, and mentorship of HCT/IEC trainees.
AB - Rapid advances in the field of hematopoietic cell transplantation (HCT), as well as the advent of immune effector cell therapy (IEC), have resulted in an increasing number of patients undergoing these therapies and an increasing level of expertise required to manage them. Previous guidelines for the training of HCT physicians were last published in 2012. In recognition of the expanding knowledge base and increasing skill set essential to the delivery of these treatment modalities, the American Society for Transplantation and Cellular Therapy Committee on Education has updated these guidelines to reflect nearly a decade of new knowledge in the field of HCT, as well as the evolution of IEC from an experimental modality to a widely used and mainstream therapy. The resulting document reflects the Committee on Education's recommended educational structure for programs engaged in the training, evaluation, and mentorship of HCT/IEC trainees.
KW - Chimeric antigen receptor T cell therapy
KW - Curriculum
KW - Education
KW - Hematopoietic cell transplantation
KW - Immune effector cell therapy
UR - http://www.scopus.com/inward/record.url?scp=85123609829&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2021.12.011
DO - 10.1016/j.jtct.2021.12.011
M3 - Article
C2 - 34954294
AN - SCOPUS:85123609829
VL - 28
SP - 125
EP - 133
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
SN - 2666-6375
IS - 3
ER -